BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34171534)

  • 1. The genetic landscape of the FAS pathway deficiencies.
    Magerus A; Bercher-Brayer C; Rieux-Laucat F
    Biomed J; 2021 Aug; 44(4):388-399. PubMed ID: 34171534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
    Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
    Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next Generation Sequencing for Detecting Somatic
    López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
    Front Immunol; 2021; 12():656356. PubMed ID: 33995372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined germline and somatic human FADD mutations cause autoimmune lymphoproliferative syndrome.
    Pellé O; Moreno S; Lorenz MR; Riller Q; Fuehrer M; Stolzenberg MC; Maccari ME; Lenoir C; Cheminant M; Hinze T; Hebart HF; König C; Schvartz A; Schmitt Y; Vinit A; Henry E; Touzart A; Villarese P; Isnard P; Neveux N; Landman-Parker J; Picard C; Fouyssac F; Neven B; Grimbacher B; Speckmann C; Fischer A; Latour S; Schwarz K; Ehl S; Rieux-Laucat F; Rensing-Ehl A; Magérus A
    J Allergy Clin Immunol; 2024 Jan; 153(1):203-215. PubMed ID: 37793571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
    Rieux-Laucat F; Magérus-Chatinet A; Neven B
    J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.
    Consonni F; Gambineri E; Favre C
    Ann Hematol; 2022 Mar; 101(3):469-484. PubMed ID: 35059842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome.
    Consonni F; Moreno S; Vinuales Colell B; Stolzenberg MC; Fernandes A; Parisot M; Masson C; Neveux N; Rosain J; Bamberger S; Vigue MG; Malphettes M; Quartier P; Picard C; Rieux-Laucat F; Magerus A
    Cell Death Dis; 2024 May; 15(5):315. PubMed ID: 38704374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation.
    Neven B; Magerus-Chatinet A; Florkin B; Gobert D; Lambotte O; De Somer L; Lanzarotti N; Stolzenberg MC; Bader-Meunier B; Aladjidi N; Chantrain C; Bertrand Y; Jeziorski E; Leverger G; Michel G; Suarez F; Oksenhendler E; Hermine O; Blanche S; Picard C; Fischer A; Rieux-Laucat F
    Blood; 2011 Nov; 118(18):4798-807. PubMed ID: 21885602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
    Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
    Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS).
    Casamayor-Polo L; López-Nevado M; Paz-Artal E; Anel A; Rieux-Laucat F; Allende LM
    Crit Rev Clin Lab Sci; 2021 Jun; 58(4):253-274. PubMed ID: 33356695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
    Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
    Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of autoimmune lymphoproliferative syndrome caused by FAS deficiency in adults.
    Lambotte O; Neven B; Galicier L; Magerus-Chatinet A; Schleinitz N; Hermine O; Meyts I; Picard C; Godeau B; Fischer A; Rieux-Laucat F
    Haematologica; 2013 Mar; 98(3):389-92. PubMed ID: 22983577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
    Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
    J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's up in the ALPS.
    Rieux-Laucat F
    Curr Opin Immunol; 2017 Dec; 49():79-86. PubMed ID: 29073495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.
    Kuehn HS; Caminha I; Niemela JE; Rao VK; Davis J; Fleisher TA; Oliveira JB
    J Immunol; 2011 May; 186(10):6035-43. PubMed ID: 21490157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
    Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
    Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
    Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
    Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome.
    Janda A; Schwarz K; van der Burg M; Vach W; Ijspeert H; Lorenz MR; Elgizouli M; Pieper K; Fisch P; Hagel J; Lorenzetti R; Seidl M; Roesler J; Hauck F; Traggiai E; Speckmann C; Rensing-Ehl A; Ehl S; Eibel H; Rizzi M
    Blood; 2016 May; 127(18):2193-202. PubMed ID: 26907631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.
    Magerus-Chatinet A; Stolzenberg MC; Lanzarotti N; Neven B; Daussy C; Picard C; Neveux N; Desai M; Rao M; Ghosh K; Madkaikar M; Fischer A; Rieux-Laucat F
    J Allergy Clin Immunol; 2013 Feb; 131(2):486-90. PubMed ID: 22857792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.
    Price S; Shaw PA; Seitz A; Joshi G; Davis J; Niemela JE; Perkins K; Hornung RL; Folio L; Rosenberg PS; Puck JM; Hsu AP; Lo B; Pittaluga S; Jaffe ES; Fleisher TA; Rao VK; Lenardo MJ
    Blood; 2014 Mar; 123(13):1989-99. PubMed ID: 24398331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.